EORTC presentations at ESMO 2014 Congress
22 Sep 2014
EORTC investigators will present the results of their cancer research at ESMO 2014 Congress, 26-30 September 2014 in Madrid.
Joint Symposium: ESMO-ASCO: The Evolution of the clinical trial landscape
Monday, September 29, 11:00 AM – 12:30 PM, Room: Granada
Can Collaborative Molecular Screening Platforms support new forms of cancer clinical research? The example of the EORTC SPECTA program.
Proffered Paper session: Melanoma and other skin tumors
Saturday, September 27, 2:00 PM – 3:45 PM, Room: Barcelona
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Karra Gurunath R, de Pril V, Suciu S, Testori A
Efficacy, safety, and quality of life data from the EORTC 18071 phase III trial of ipilimumab versus placebo after complete resection of stage III melanoma
Proffered Paper session: Sarcoma
Monday, September 29, 3:45 PM – 5:30 PM, Room: Sevilla
W.T.A. van der Graaf, A. Le Cesne, O. Mir, H. Gelderblom, A. Italiano, S. Marreaud, I. Judson, S. Litiere
Outcome of first-line treatment of elderly advanced soft tissue sarcoma (STS) patients: a pooled analysis of eleven EORTC Soft Tissue and Bone Sarcoma Group trials
Proffered Paper session: Breast Cancer, early stage
Abstract: 7324
H. Bonnefoi, W. Jacot, M. Saghatchian, C. Moldovan, L. Venat-Bouvet, K. Zaman, E. Matos, T. Petit, M. Debled, A. Bodmer, P. Vuylsteke, G. Jerusalem, E. Brain, O. Tredan, C.G.M. Messina, L. Slaets, D. Cameron
Neoadjuvant treatment with docetaxel plus lapatinib (L), trastuzumab (T), or both followed by an anthracycline based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study
Poster Discussion session: Immunotherapy of cancer
Sunday, September 28, 2014, 1:00 PM – 2:00 PM. Room: Valencia
Erik Tanis, Catherine Julie, Jean-Francois Emile, Bernard Nordlinger, Murielle Mauer, Arnaud Roth, Manfred Lutz, Daniela Aust, Theo Ruers
Prognostic impact of immune response in resectable colorectal liver metastases treated with and without perioperative FOLFOX chemotherapy
Poster Discussion session: Gastrointestinal tumours, colorectal
Saturday, September 27, 1:00 PM – 2:00 PM, Room: Granada
H-J. Schmoll, K. Haustermans, T. Price, B. Nordlinger, R.D. Hofheinz, J-F. Daisne, J. Janssens, B. Brenner, P. Schmidt, H. Reinel, S. Hollerbach, K. Caca, F. Fauth, C.V. Hannig, J. Zalcberg, N. Tebbutt, M.E. Mauer, C. Messina, M.P. Lutz, E. Van Cutsem
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: interim analysis for disease free survival of PETACC-6
ESMO-SEOM Joint Symposium
Monday, September 29, 2:15 PM – 3:45 PM, Room: Granada
The European Perspective of Academic Research: The way to move forwards
Poster Display session: Melanoma and other skin tumours
Monday, September 29, 1:00 PM – 2:00 PM, Room: Valencia
S. Suciu, A.M.M. Eggermont, P. Lorigan, J. Kirkwood, S. Markovic, C. Garbe, D. Cameron, S. Kotapati, C. Konto, T.-T. Chen, K. Wheatley, N. Ives, G. De Schaetzen, A. Efendi, M. Buyse
Relapse-free survival (RFS) as a surrogate endpoint for overall survival in adjuvant Interferon trials in patients with resectable cutaneous melanoma: an individual patient data meta-analysis
Poster Display session
Saturday, September 27, 12:45 PM – 1:45 PM, Room: Poster area
Mary 0’Brien, Rabab Gaafar, Baktiar Hasan, Jessica Menis, Tanja Cufer, Sanjay Popat, Penella Woll, Veerle Surmont, Vassilis Georgoulias, Ana Montes, Fiona Blackhall, Ivo Hennig, Gerald Schmid-Bindert, Paul Baas, on behalf of the EORTC Lung Cancer Group
Double blind randomized phase III study of maintenance Pazopanib® versus Placebo in non-Small Cell Lung Cancer patients non progressive after first line chemotherapy (EORTC Lung Cancer Group, 08092): MAPPING
Patient Advocacy Track
Anastassia Negrouk and Denis Lacombe will participate in the 2014 ESMO Patient Advocacy Track.
Saturday, September 27, 10:10 – 10:25, Room: Palma
Pros and Cons of new EU Clinical Trials Regulation
Saturday, September 27, 10:45 – 11:30, Room: Palma
Regulatory process to involve patients in discussions on clinical trial endpoints
Saturday, September 27, 11:50 – 12:00, Room: Palma
How can patients be involved in protocol development
Rare Cancers Europe: Special Session: How CT could have been done, and where not, in rare cancers
Monday, September 29, 16:00 – 17:30, Room: Bilbao
Methodological challenges in rare cancers
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023